A Randomised, Double-Blind, Placebo-Controlled Trial with Vitamin D3 in MS: Subgroup Analysis of Patients with Baseline Disease Activity Despite Interferon Treatment
Table 3
Clinical outcomes in vitamin D- and placebo-treated active subgroup patients.
Vitamin D
Placebo
value
Baseline
Month 12
Baseline
Month 12
EDSS mean (SD) change
2.2 (0.9)
1.9 (1.1)
1.9 (1.2)
2.0 (1.5)
0.274
−0.3 (0.6)
−0.1 (0.7)
ARR, mean (SD)
0.67 (0.38)
0.33 (0.62)
0.83 (0.37)
0.47 (0.74)
NS
TTW10, mean (SD) change (seconds)
12.17 (6.27)
10.36 (2.70)
10.35 (7.39)
12.10 (13.5)
0.820
−2.32 (4.62)
1.16 (7.65)
T25FW, mean (SD) change (seconds)
7.26 (7.8)
5.27 (1.4)
4.54 (0.94)
5.08 (1.14)
0.860
−1.85 (8.1)
0.44 (0.92)
EDSS: Expanded Disability Status Scale; ARR: annual relapse rate; TTW10: timed 10-foot tandem walk; T25FW: timed 25-foot walk.